Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-04-30

Study Completion Date

2007-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rituximab has been demonstrated to sensitize drug-resistant NHL cells to the cytotoxic actions of several chemotherapy agents by enhancing sensitivity of tumor cells to chemotherapy-induced apoptosis. Gemcitabine, a nucleoside analog that is used in several other malignancies, has shown very promising activity in patients with refractory Hodgkin's disease and low-grade NHL. The combination of rituximab and gemcitabine may have synergistic cytotoxic action in patients with relapsed or refractory DLBCL and possibly lead to improved response rates and demonstrable clinical benefit.

This trial will investigate the efficacy the combination of rituximab and gemcitabine in treating patients with relapsed or refractory DLBCL.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

NCT06213311

B Cell Lymphoma

RECRUITING PHASE2

Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT02077166

Relapsed Diffuse Large B-Cell Lymphoma Refractory Diffuse Large B-Cell Lymphoma

COMPLETED PHASE1/PHASE2

Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

NCT01729104

Lymphoma

TERMINATED PHASE1

Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT04285268

High Grade B-Cell Lymphoma, Not Otherwise Specified Recurrent Burkitt Lymphoma Recurrent Diffuse Large B-Cell Lymphoma +4 more

WITHDRAWN PHASE2

A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma

NCT02811679

Non-Hodgkin Lymphoma

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OUTLINE: This is a multi-center study.

* Rituximab 375 mg/m2 day 1 of 21 day cycle
* Gemcitabine 1000 mg/m2 days 1 and 8 of 21 day cycle

Subgroup 1. Relapsed after responding to first line chemotherapy, who are not candidates for salvage high-dose chemotherapy.

Subgroup 2. Failure to achieve a complete response or relapsed after responding to salvage chemotherapy (any number of salvage regimens allowed), who are not candidates for high-dose chemotherapy.

Subgroup 3. Refractory to first line chemotherapy and/or 1 (one) salvage chemotherapy regimen.

Subgroup 4. Progression after high-dose chemotherapy. Patients with progressive disease within 3 months of high-dose chemotherapy are not allowed.

Performance Status: ECOG performance status 0, 1, 2

Life expectancy: Not specified

Hematopoietic:·

* ANC ≥ 1,000/mm3·
* Platelets ≥ 100,000/mm3

Hepatic:·

* Total bilirubin ≤ 2.0 x ULN·
* ALT and AST ≤ 3 x ULN unless lymphoma involves the liver on CT scan then AST and ALT can be \< 5 x ULN

Renal:·

* Serum creatinine ≤ 2.0 mg/dl (except for patients on dialysis)

Cardiovascular:·

* Not specified

Pulmonary:·

* Not specified

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoma, B-Cell

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Rituximab + Gemcitabine for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Group Type EXPERIMENTAL

Rituximab

Intervention Type DRUG

Rituximab 375 mg/m2, day 1 of 21 day cycle

Gemcitabine

Intervention Type DRUG

Gemcitabine 1000 mg/m2, days 1 and 8 of 21 day cycle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rituximab

Rituximab 375 mg/m2, day 1 of 21 day cycle

Intervention Type DRUG

Gemcitabine

Gemcitabine 1000 mg/m2, days 1 and 8 of 21 day cycle

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Biopsy-proven DLBCL which meet the criteria of any of the 4 subgroups
* Transformed DLBCL from a previous indolent NHL which meet the criteria of any of the 4 subgroups and have received at least one standard chemotherapy regimen for aggressive NHL or a biopsy upon progression of disease has been obtained to confirm the presence of DLBCL. The concomitant presence of a component of low grade lymphoma will NOT exclude participation
* Measurable disease per Standardized Response Criteria for Non-Hodgkin's Lymphoma
* Prior gemcitabine therapy is allowed.
* Negative pregnancy test

Exclusion Criteria

* No history of life-threatening reactions to rituximab.
* No history of gemcitabine intolerance; prior gemcitabine therapy is allowed.
* No history of malignancy in the last 5 years (basal cell carcinoma of the skin excluded).
* No central nervous system or cerebrospinal fluid involvement
* No other investigational drugs received within 30 days prior to being registered for protocol therapy.
* No active infections.
* No current breastfeeding

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No